Cancer is a diverse group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Increasingly, roles for the upregulation of certain ion channels and transporters in cancer is being described and understood. We are actively working with leading scientists at the forefront of cancer and ion channel research in the dual aims of developing biomarker assays and effective and reliable drug screening methods.
Different cancers upregulate different ion channels and transporters. Specific pharmaceutical targeting of these proteins could lead to effective and safe therapeutic tools.
ICTs as Cancer Biomarkers – Increasing early diagnostic capabilities of cancer would benefit countless numbers of patients. In many cancers, certain ion channels and transporters (ICT) are upregulated and expressed in much greater numbers than usual. We are actively collaborating with several academic groups to develop high throughput ICT biomarker screens
ICTs as Therapeutic Targets in Cancer Therapy – The upregulation of certain ICTs in some cancers, as well as the roles that they play in cell proliferation and migration, indicates that ICTs may offer a useful therapeutic option in cancer treatment. The ICR is well suited to assays aimed at targeting electrogenic membrane proteins involved in cancer.